Financials Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
1.03 USD -3.74% Intraday chart for Lineage Cell Therapeutics, Inc. -5.50% -5.50%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 111.3 133.3 264 413 198.9 201.7 201.7 -
Enterprise Value (EV) 1 111.3 133.3 264 413 198.9 201.7 201.7 201.7
P/E ratio -2.54 x -11.1 x -12.6 x -9.42 x -7.8 x -8.08 x -11.9 x -7.93 x
Yield - - - - - - - -
Capitalization / Revenue 22.3 x 37.9 x 145 x 95.1 x 13.5 x 20.8 x 10.1 x 9.76 x
EV / Revenue 22.3 x 37.9 x 145 x 95.1 x 13.5 x 20.8 x 10.1 x 9.76 x
EV / EBITDA -2.66 x -3.73 x -10.8 x -8.54 x -9.13 x -7.82 x -10 x -12.1 x
EV / FCF -3.45 x - - - 308 x -5.45 x -30.1 x -9.84 x
FCF Yield -29% - - - 0.32% -18.3% -3.32% -10.2%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 121,904 149,794 149,991 168,558 169,976 188,478 188,478 -
Reference price 2 0.9130 0.8900 1.760 2.450 1.170 1.070 1.070 1.070
Announcement Date 3/14/19 3/12/20 3/11/21 3/10/22 3/9/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 4.988 3.515 1.826 4.341 14.7 9.701 20.03 20.66
EBITDA 1 -41.8 -35.75 -24.34 -48.34 -21.79 -25.8 -20.1 -16.7
EBIT 1 -41.8 -38.88 -26.45 -49.21 -22.52 -24.49 -20.83 -22.35
Operating Margin -837.91% -1,106% -1,448.36% -1,133.63% -153.17% -252.42% -104.01% -108.2%
Earnings before Tax (EBT) 1 -47.13 -19.23 -21.92 -43.27 -25.81 -24.32 -16.26 -23.85
Net income 1 -45.99 -11.71 -20.65 -43.02 -26.27 -22.94 -16.22 -23.85
Net margin -922.01% -333.12% -1,130.83% -990.99% -178.69% -236.51% -80.98% -115.46%
EPS 2 -0.3600 -0.0800 -0.1400 -0.2600 -0.1500 -0.1325 -0.0900 -0.1350
Free Cash Flow 1 -32.3 - - - 0.646 -37 -6.7 -20.5
FCF margin -647.49% - - - 4.39% -381.4% -33.46% -99.24%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/14/19 3/12/20 3/11/21 3/10/22 3/9/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 0.9 0.512 2.27 1.168 5.237 4.553 2.998 1.915 2.386 3.225 1.246 2.844 0.623 0.1925 0.1925 15.94
EBITDA 1 -11.89 -6.883 -6.644 -28.05 -6.214 -4.055 -5.058 -6.466 -6.471 -4.854 -6.529 -7.4 - - - -
EBIT 1 - -7.08 -6.843 -28.24 -6.396 -4.234 -5.251 -6.639 -6.642 -5.024 -6.705 -5.774 -8.862 -10.18 -11.02 4.588
Operating Margin - -1,382.81% -301.45% -2,417.64% -122.13% -92.99% -175.15% -346.68% -278.37% -155.78% -538.12% -202.99% -1,422.47% -5,286.49% -5,722.86% 28.78%
Earnings before Tax (EBT) 1 -14.96 -4.965 -8.846 -28.01 -7.093 -6.782 -5.575 -6.362 -6.207 -5.203 -7.158 -5.787 -8.077 -10.71 -11.99 19.22
Net income 1 -14.92 -4.788 -7.823 -28.99 -7.087 -6.763 -6.069 -6.354 -4.372 -5.229 -7.11 -7.633 -8.029 -10.66 -11.94 19.27
Net margin -1,657.78% -935.16% -344.63% -2,482.02% -135.33% -148.54% -202.43% -331.8% -183.24% -162.14% -570.63% -268.36% -1,288.76% -5,536.62% -6,201.56% 120.87%
EPS 2 -0.1000 -0.0300 -0.0500 -0.1700 -0.0400 -0.0400 -0.0400 -0.0300 -0.0300 -0.0300 -0.0400 -0.0300 -0.0400 -0.0600 -0.0600 0.1000
Dividend per Share - - - - - - - - - - - - - - - -
Announcement Date 8/6/20 8/12/21 11/10/21 3/10/22 5/12/22 8/11/22 11/10/22 3/9/23 5/11/23 8/10/23 11/9/23 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -32.3 - - - 0.65 -37 -6.7 -20.5
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 1.42 0.44 - - 0.41 - - -
Capex / Sales 28.37% 12.52% - - 2.81% - - -
Announcement Date 3/14/19 3/12/20 3/11/21 3/10/22 3/9/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.07 USD
Average target price
5.4 USD
Spread / Average Target
+404.67%
Consensus
  1. Stock
  2. Equities
  3. Stock Lineage Cell Therapeutics, Inc. - Nyse
  4. Financials Lineage Cell Therapeutics, Inc.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer